血浆半乳糖缺陷型IgA1与C3比值与IgA肾病CKD进展相关
该队列研究纳入1210例经活检证实的IgA肾病患者,测量活检时血浆半乳糖缺陷型IgA1(Gd-IgA1)和补体C3浓度,分析其与CKD进展事件(ESKD或eGFR下降50%)的关联。中位随访43个月,172例(14%)发生进展事件。调整传统危险因素后,Gd-IgA1/C3比值每增加一个自然对数单位,CKD进展风险独立增加(HR 2.03,95%CI 1.25-3.29,P=0.004),而Gd-IgA1水平与风险呈非线性关系(>325 U/ml后平台)。
要点
- Gd-IgA1/C3比值与CKD进展独立相关,每自然对数单位HR 2.03。
- Gd-IgA1水平与CKD进展呈非线性关系,>325 U/ml后风险不再增加。
- Gd-IgA1/C3比值最高四分位者进展风险是最低四分位的2.17倍。
核心结论
- 在IgA肾病中,血浆Gd-IgA1/C3比值与CKD进展事件独立相关,不受临床和病理特征影响。
研究设计与样本
- 队列研究,纳入北京大学第一医院1210例经活检证实的IgA肾病患者,活检时检测血浆Gd-IgA1和C3浓度。
主要发现
- 中位随访43个月(IQR 24-76),172例(14%)发生CKD进展事件(ESKD或eGFR下降50%)。
- Gd-IgA1水平与CKD进展风险呈非线性关系,>325 U/ml后风险达平台。
- Gd-IgA1/C3比值与CKD进展风险呈单调递增关系。
- 调整传统危险因素后,Gd-IgA1/C3比值每自然对数单位HR 2.03(95%CI 1.25-3.29,P=0.004)。
- 以第一四分位为参照,第二、三、四四分位HR分别为1.71(95%CI 1.01-2.89)、1.55(95%CI 0.91-2.63)、2.17(95%CI 1.33-3.56)。
临床怎么用
- 检测活检时血浆Gd-IgA1/C3比值可能有助于识别CKD进展高危的IgA肾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Increased circulating galactose-deficient IgA1 and subsequently complement activation both play important roles in the pathophysiology of IgA nephropathy. However, their relationship to disease severity and progression remains unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We assessed 1210 participants in a cohort study of biopsy-proven IgA nephropathy at Peking University First Hospital. Plasma concentrations of galactose-deficient IgA1 and complement component C3 were measured at the time of biopsy. We tested associations of galactose-deficient IgA1 and galactose-deficient IgA1/C3 ratio with CKD progression event, defined as ESKD or 50% decline in eGFR, using Cox proportional hazards models and restricted cubic splines. RESULTS: After a median follow-up of 43 months (interquartile range, 24-76 months), 172 (14%) participants reached the CKD progression event. The association of galactose-deficient IgA1 levels and CKD progression event showed a nonlinear relationship. The risk of CKD progression events was greater with higher plasma galactose-deficient IgA1 levels but reached a plateau when galactose-deficient IgA1>325 U/ml, whereas the risk of CKD progression events monotonically increased with higher galactose-deficient IgA1/C3 ratio. After adjustment for traditional risk factors (demographics, eGFR, proteinuria, hypertension, Oxford pathologic score, and corticosteroids/immunosuppressive therapy), higher levels of galactose-deficient IgA1/C3 ratio were independently associated with CKD progression event (per natural log-transformed [galactose-deficient IgA1/C3], hazard ratio, 2.03; 95% confidence interval [95% CI], 1.25 to 3.29; P=0.004). In reference to the first quartile of the galactose-deficient IgA1/C3 ratio, hazard ratios were 1.71 (95% CI, 1.01 to 2.89) for the second quartile, 1.55 (95% CI, 0.91 to 2.63) for the third quartile, and 2.17 (95% CI, 1.33 to 3.56) for the fourth quartile. CONCLUSIONS: In IgA nephropathy, plasma galactose-deficient IgA1/C3 ratio was associated with CKD progression event independent of clinical and biopsy characteristics.
引用
- Chen P, Yu G, Zhang X, et al. Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy. Clin J Am Soc Nephrol. 2019. PMID: 31511226. doi:10.2215/CJN.13711118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。